IDEXX Laboratories, Inc. (IDXX) Stock Price & Analysis
IDEXX Laboratories, Inc. (IDXX) closed at USD 566.76 on Thursday, October 22, 2026, up 2.40% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 553.48; the Oct 22, 2026 session ranged USD 558.99–568.67 on volume of 430,106 shares. Market capitalization is $44.65B, with a 52-week range of USD 500.61–769.98 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IDXX.md
Key facts (IDXX)
- Last four reported quarters (through Jun 30, 2026): revenue $4.55B, net income $1.14B (25.0% margin), free cash flow $1.25B (SEC filings).
- 6 of 80 tracked superinvestors hold IDXX (13F, Q2 2026): 1 new, 0 added, 3 reduced, 2 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $1.2M; 1 not under a Rule 10b5-1 plan ($1.2M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y -11.3% vs S&P 500 +14.9%; 5Y -13.1% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 3.72, revenue estimate $1.19B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IDXX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.22B | $3.37B | $3.66B | $3.90B | $4.30B | $4.55B |
| Gross profit | $1.89B | $2.00B | $2.19B | $2.38B | $2.66B | — |
| Operating income | $932M | $899M | $1.10B | $1.13B | $1.36B | $1.46B |
| Net income | $745M | $679M | $845M | $888M | $1.06B | $1.14B |
| EPS (diluted) | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 | — |
| Free cash flow | $636M | $394M | $773M | $808M | $1.06B | $1.25B |
| Gross margin | 58.8% | 59.5% | 59.8% | 61.0% | 61.8% | — |
| Operating margin | 29.0% | 26.7% | 30.0% | 29.0% | 31.6% | 32.0% |
| Net margin | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% | 25.0% |
| Revenue growth | +18.8% | +4.7% | +8.7% | +6.5% | +10.4% | — |
| Cash + short-term investments | $144M | $113M | $454M | $288M | $180M | — |
| Total debt | $851M | $770M | $698M | $618M | $450M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (IDXX)
P/E at fiscal year-ends: Dec 2025 51.7x, Dec 2024 38.8x, Dec 2023 55.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (IDXX)
6 of 80 tracked investors hold IDXX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Terry Smith | Fundsmith | 3.93% | $537M | Reduced -30.4% |
| Polen Capital | Polen Capital Management | 2.41% | $280M | Reduced -23.5% |
| Jensen Investment Management | 1.35% | $55.6M | New position | |
| Wallace Weitz | Weitz Investment Management | 1.29% | $18.6M | Unchanged |
| Mairs & Power | Mairs & Power Funds | 0.01% | $1.1M | Unchanged |
| Bill Nygren | Oakmark Funds | <0.01% | $240K | Reduced -5.6% |
Insider sales (SEC Form 4, open-market, last ~7 months) (IDXX)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Kingsley Lawrence D | Director | 2,203 | $1.2M | 18.7% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (IDXX)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | JP Morgan | Target lowered | Overweight | $775 → $750 |
| 2026-10-12 | Keybanc | Initiated | Sector Weight | |
| 2026-08-11 | Barclays | Target lowered | Overweight | $800 → $710 |
| 2026-08-05 | UBS | Target raised | Neutral | $620 → $670 |
| 2026-08-05 | Citigroup | Target raised | Neutral | $650 → $670 |
| 2026-07-27 | UBS | Target lowered | Neutral | $640 → $620 |
Total return (dividends reinvested) (IDXX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -11.3% | -13.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -11.3% | -2.8% |
| Volatility (annualized) | 32.0% | 33.8% |
| Max drawdown | -34.2% (Nov 2025→Sep 2026) | -51.3% (Oct 2021→Oct 2022) |
IDXX revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| CAG | $1.12B | 91.9% | +9.4% |
| Water segment revenue | $58.6M | 4.8% | +14.8% |
| LPD | $35.2M | 2.9% | +10.8% |
| Total revenue | $1.22B | 100% | — |
IDXX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| CAG Diagnostics Recurring Revenue | $974.7M | 80.1% | +11.0% |
| — Vet Lab Consumables (part of CAG Diagnostics Recurring Revenue) | $430.3M | 35.4% | +14.7% |
| — Reference Laboratory Diagnostic & Consulting Services (part of CAG Diagnostics Recurring Revenue) | $406.7M | 33.4% | +10.6% |
| — Rapid Assay Products (part of CAG Diagnostics Recurring Revenue) | $101.6M | 8.3% | +1.3% |
| — CAG Diagnostics Service & Accessories (part of CAG Diagnostics Recurring Revenue) | $36.1M | 3.0% | +3.2% |
| Product revenue | $718.6M | 59.1% | +9.3% |
| — Service revenue (part of Product revenue) | $498.0M | 40.9% | +10.2% |
| — Veterinary Software Services & Diagnostic Imaging Systems (part of Product revenue) | $96.3M | 7.9% | +12.2% |
| — Recurring Revenue (part of Product revenue) | $76.3M | 6.3% | +10.7% |
| — CAG Diagnostic Capital Instruments (part of Product revenue) | $47.2M | 3.9% | -19.5% |
| Systems & Hardware | $20.0M | 1.6% | +18.4% |
| Total revenue | $1.22B | 100% | — |
IDXX revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $773.0M | 63.5% | +7.7% |
| Europe, the Middle East and Africa | $265.5M | 21.8% | +13.8% |
| Asia Pacific | $101.5M | 8.3% | +13.7% |
| Canada | $50.8M | 4.2% | +8.8% |
| Latin America & Caribbean | $25.8M | 2.1% | +15.6% |
| Total revenue | $1.22B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
IDXX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | THERMO FISHER SCIENTIFIC INC. (TMO) | “We also distribute certain water testing kits manufactured by Thermo Fisher Scientific, Inc. that complement our Cryptosporidium and Giardia testing products.” |
Quoted from the company's 10-K filed Feb 20, 2026.
IDXX company outlook (results filed Aug 4, 2026)
- “The Company is updating its full year revenue growth guidance range to $4,700 million - $4,745 million, or reported growth of 9.1% - 10.3%, an increase of $5 million at midpoint, net of a $15 million reduction to projected revenues from a stronger U.S. dollar.”
- “The Company is increasing its outlook for organic revenue growth to 8.5% - 9.7%, an increase of 0.4% at midpoint, reflecting operational performance.”
- “The Company increased its full year reported operating margin outlook to 32.3% - 32.5%, bringing the projected full year operating profit margin expansion to 70 - 90 basis points as reported and on a comparable basis.”
- “The Company updated its EPS outlook range to $14.69 - $14.94, reflecting increased reported growth of 12% - 14% and 13% - 15% comparable growth.”
Quoted word-for-word from the SEC 8-K results press release.
IDXX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $3.72 | $3.78 | -1.8% | $1.19B | 11 |
| Next quarter (ends Dec 2026) | $3.36 | $3.45 | -2.5% | $1.17B | 10 |
| Current fiscal year (ends Dec 2026) | $14.84 | $14.66 | +1.2% | $4.72B | 12 |
| Next fiscal year (ends Dec 2027) | $16.74 | $16.52 | +1.4% | $5.15B | 13 |
Key Statistics (as of October 23, 2026 at 09:22 UTC)
| Price | USD 566.76 |
|---|---|
| Change | ▲ 2.40% (up) |
| Previous Close | USD 553.48 |
| Open | USD 562.01 |
| Day Range | USD 558.99 – 568.67 |
| 52-Week Range | USD 500.61 – 769.98 |
| Volume | 430,106 shares |
| Market Cap | $44.65B |
| Exchange | NMS |
Technical Analysis (IDXX)
Nexqual's technical model rates IDXX "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:22 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 65.67 (neutral) |
| vs SMA50 | Above (USD 533.14) |
| MACD | 8.35 (positive) |
Earnings (IDXX)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD 3.72 |
| Revenue Estimate | $1.19B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 4.27 vs est 3.93 ▲ beat |
| 2026-03-31 | USD 3.47 vs est 3.41 ▲ beat |
| 2025-12-31 | USD 3.08 vs est 2.94 ▲ beat |
| 2025-09-30 | USD 3.4 vs est 3.15 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Financials & Fundamentals (IDXX)
| Total Revenue | $4.55B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.70% |
| Gross Margin | +62.45% |
| Operating Margin | +34.98% |
| Profit Margin | +25.03% |
| ROE | +74.21% |
| Debt / Equity | 0.68 |
| Current Ratio | 1.17 |
| Total Cash | $196.93M |
| Total Debt | $1.10B |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Ownership (IDXX)
| Insider Ownership | +0.22% |
|---|---|
| Institutional Ownership | +96.60% |
| Shares Outstanding | 78.78M |
| Float | 78.50M |
| Short % of Float | +2.82% |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
From IDEXX Laboratories, Inc.'s Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Several of these point-of-care analyzers, including the Catalyst One Chemistry analyzer, ProCyte One hematology analyzer, SediVue Dx Analyzer, and IDEXX inVue Dx Cellular Analyzer, utilize proprietary AI capabilities in their image capture systems to analyze samples.
- The FDA's Quality System regulations set forth standards for our product design and manufacturing processes, require the maintenance of certain records, and provide for inspections of our facilities by the FDA.
- VetConnect PLUS enables greater medical insight and enhanced decision-making through IDEXX DecisionIQ, an analytical tool incorporated in VetConnect PLUS that utilizes proprietary technology, including AI, to aid practitioners in making medical diagnoses.
- We have developed and are executing a greenhouse gas emissions reduction strategy.
Legal & Regulatory Risks (Item 1A, quoted)
- The nature of our global operations subjects us to local, state, regional, and federal tax laws in jurisdictions around the world. Our future tax expense could be affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, or changes in tax laws or their interpretation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WAT | Waters Corporation | USD 455.59 | ▼ 0.41% |
| IQV | IQVIA Holdings, Inc. | USD 278.32 | ▲ 0.61% |
| ILMN | Illumina, Inc. | USD 269.4 | ▼ 4.76% |
| A | Agilent Technologies, Inc. | USD 173.89 | ▼ 2.17% |
| NTRA | Natera, Inc. | USD 401.37 | ▼ 2.91% |
| MTD | Mettler-Toledo International, I | USD 1,684.64 | ▲ 0.4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt